Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial

ABSTRACT: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis with severe blistering. No curative treatment is available. Scientific data indicated that epigallocatechin-3-gallate (EGCG), a green tea extract, might improve the phenotype of RDEB patients. In a multicentre, rand...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Orphanet J Rare Dis
Asıl Yazarlar: Chiaverini, Christine, Roger, Coralie, Fontas, Eric, Bourrat, Emmanuelle, Bourdon-Lanoy, Eva, Labrèze, Christine, Mazereeuw, Juliette, Vabres, Pierre, Bodemer, Christine, Lacour, Jean-Philippe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Letter to the Editor
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807580/
https://ncbi.nlm.nih.gov/pubmed/27015660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-016-0411-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller